Abstract
AbstractAdvanced materials, and nanomaterials, are promising for healthcare applications and are in particular in the spotlight of medical innovation since rapidly developed nano-formulated vaccines provide relief in the SARS-CoV-2 pandemic. Further increased rapid growth is to be expected as more and more products are in development and reach the market, beneficial for human health. However, the human body is not a dead end and these products are likely to enter the environment, whereas their fate and effects in the environment are unknown. This part of the life-cycle of advanced medicinal products tends to be overlooked, if the perspective is human-centered and excludes the connectedness of human activity with, and consequences for our environment. Gaps are reviewed that exist in awareness, perspective taking, inclusion of environmental concerns into research and product development and also in available methodologies and regulatory guidance. To bridge these gaps, possible ways forward start to emerge, that could help to find a more integrative way of assessing human and environmental safety for advanced material medicinal products and nanomedicines.
Publisher
Springer Science and Business Media LLC
Reference81 articles.
1. Giese B Drapalik M Zajicek L Jepsen D Reihlen A Zimmermann T 2020 Advanced materials: overview of the field and screening criteria for relevance assessment UBA TEXTE 132/2020 Available via https://www.umweltbundesamt.de/en/publikationen/advanced-materials-overview-of-the-field-screening Accessed 10 Mar 2022
2. Kennedy A, Brame J, Rycroft T, Wood M, Zemba V, Weiss CJ et al (2019) A definition and categorization system for advanced materials: the foundation for risk-informed environmental health and safety testing. Risk Anal 39(8):1783–1795. https://doi.org/10.1111/risa.13304
3. Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR (2019) Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. Nanomedicine 14(1):93–126. https://doi.org/10.2217/nnm-2018-0120
4. Halamoda-Kenzaoui B, Box H, Van Elk M, Gaitan S, Geertsma R, Gainza Lafuente E et al (2019) Anticipation of regulatory needs for nanotechnology-enabled health products—the REFINE white paper. Publ Office Eur Union. https://doi.org/10.2760/599552
5. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M et al (2020) COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586(7830):594–599. https://doi.org/10.1038/s41586-020-2814-7
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献